New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
09:10 EDTBIIB, LTD, TGT, FDO, KSS, JWN, GPS, MLNX, SPWR, ROSTOn The Fly: Pre-market Movers
HIGHER AFTER SSS REPORTS: Ross Stores (ROST), up 5.1%... Nordstrom (JWN), up 3.5%... Target (TGT), up 2.9%... ALSO HIGHER: Gap (GPS), up 4% after report of December SSS up 5%, along with $1B stock-buyback plan and deal to buy Intermix for $130M... SunPower (SPWR), up 15.5% after upgrade to Buy at Lazard Capital... LOWER AFTER EARNINGS: Family Dollar (FDO), down 9.6%... LOWER AFTER SSS REPORTS: Limited (LTD), down 5%... Kohl's (KSS), down 2.4%... ALSO LOWER: Melanox (MLNX), down 18.6% after Q4 revenue warning prompts numerous price target cuts around Street... Biogen Idec (BIIB), down 5.4% after ALS drug misses endpoint, development discontinued.
News For GPS;FDO;ROST;JWN;TGT;SPWR;KSS;LTD;MLNX;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 2, 2015
07:11 EDTBIIBApplied Genetic Technologies to resume trading at 7:30 am EDT
Subscribe for More Information
07:06 EDTBIIBBiogen, AGTC enter collaboration to develop gene therapies in ophthalmology
Biogen (BIIB) and AGTC (AGTC) announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases. The collaboration will focus on the development of a portfolio of AGTC’s therapeutic programs, including both a clinical stage candidate and a pre-clinical candidate for orphan diseases of the retina that can lead to blindness in children and adults. The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC by Biogen and a license agreement for manufacturing rights. Biogen will make an upfront payment in the amount of $124M to AGTC, which includes a $30M equity investment in AGTC at a price equal to $20.63 per share and certain prepaid research and development expenditures. Biogen will be granted a license to the XLRS and XLRP programs and the option to license discovery programs for three additional indications at the time of clinical candidate selection. Under the collaboration, AGTC is eligible to receive upfront and milestone payments exceeding $1B. This includes up to $472.5M collectively for the two lead programs, which also will carry royalties in the high single digit to mid-teen percentages of annual net sales. In addition, Biogen will make payments up to $592.5M across the discovery programs, along with royalties in the mid single digits to low teen percentages of annual net sales. Biogen obtains worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the United States. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. Biogen will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, Biogen will receive an exclusive license to use AGTC’s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC’s discretion, in exchange for payment of milestones and royalties. The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States, and is expected to close in the third calendar quarter of 2015.
July 1, 2015
16:53 EDTFDOFamily Dollar reports Q3 adjusted EPS 74c, consensus 82c
Subscribe for More Information
09:46 EDTTGTCriteo rises after said to add Alibaba, Target as customers
Shares of digital marketing solutions provider Criteo (CRTO) are rising in early trading after research firm Pacific Crest raised its price target on the stock. The firm also notes that it appears Criteo has recently added Alibaba (BABA) and Target (TGT) as customers. WHAT'S NEW: In a note to investors this morning, Pacific Crest analyst Evan Wilson said that the firm's checks indicate that Criteo now has cookies on 49% of the top 100 retail and travel websites in the U.S. Wilson noted that Google (GOOG) has 76% of the top 100, but suggested also that its heavy overlap with Criteo reinforces the view that the two companies' cookies serve different purposes. Wilson said Target was a notable Criteo win in the U.S. during Q2, while also saying the firm discovered that some Alibaba sites outside of China now have a Criteo cookie for the first time. Wilson raised his 2016 estimates for Criteo citing the continued strong checks and increased the firm's price target on the stock to $65 from $55. PRICE ACTION: In early trading, Criteo grained $2.30, or 4.8%, to $49.97.
07:30 EDTSPWRDrop is Solar stocks a buying opportunity, says Deutsche Bank
Deutsche Bank analyst Vishal Shah attributes the recent weakness in the Solar space to investor concerns around increased interest rate and growth uncertainty, especially of YieldCos. Shah, however, views YieldCos as a significant growth catalyst for the solar and broader renewables sector. The analyst expects the current weakness to provide an attractive entry point for longer term investors. Publicly traded companies in the space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL) and Yingli Green Energy (YGE).
June 30, 2015
07:28 EDTFDODollar Tree shares poised to outperform, says Wells Fargo
Wells Fargo predicts that Dollar Tree will be re-ranked by quantitative investment models following its merger with Family Dollar (FDO), enabling Dollar Tree's stock to outperform. The firm predicts that Dollar Tree's P/E ratio will become much lower versus its peers after the merger closes. Wells keeps an Outperform rating on Dollar Tree.
June 29, 2015
06:20 EDTGPSGap plans two flagship stores for brands in Times Square, WSJ reports
Subscribe for More Information
June 26, 2015
14:25 EDTGPSGap to take over Toys R Us location in Times Square, CNBC reports
Subscribe for More Information
10:00 EDTTGTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARM Holdings (ARMH) downgraded to Underperform from Market Perform at Bernstein... Apogee Enterprises (APOG) downgraded to Market Perform from Outperform at Northland... Atlas Resource Partners (ARP) downgraded to Underperform from Neutral at BofA/Merrill... Bank of the Ozarks (OZRK) downgraded to Hold from Buy at Drexel Hamilton... China Cord Blood (CO) downgraded to Neutral from Buy at Roth Capital... Citizens Financial (CFG) downgraded to Neutral from Buy at Guggenheim... Community Health (CYH) downgraded to Market Perform from Outperform at Raymond James... Eagle Bancorp (EGBN) downgraded to Hold from Buy at Sandler O'Neill... Fifth Street Senior (FSFR) downgraded to Neutral from Buy at UBS... FireEye (FEYE) downgraded to Equal Weight from Overweight at Barclays... Insight Enterprises (NSIT) downgraded to Underperform at Raymond James... Micron (MU) downgraded to Neutral from Buy at Mizuho... SYNNEX (SNX) downgraded to Hold from Buy at Needham... Swatch Group (SWGAY) downgraded to Equal Weight from Overweight at Barclays... Target (TGT) downgraded to Market Perform from Outperform at BMO Capital... Zoetis (ZTS) downgraded to Market Perform from Outperform at BMO Capital.
07:40 EDTTGTTarget downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Target to Market Perform citing near-term leadership uncertainty at a time when shares are trading near 52 week and all-time highs. BMO Capital's analyst said it was surprised by the announcement that Kathee Tesija, EPV and Chief Merchandising and Supply Chain Officer will transition into an advisory role but does not view it as a disagreement in strategic direction.
05:21 EDTBIIBBiogen, Sobi announce EMA validates MAA for Alprolix
Biogen and Swedish Orphan Biovitrum AB, or Sobi, announced that the European Medicines Agency, or EMA, has accepted the Marketing Authorization Application, or MAA, of Alprolix, a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. This validation signifies the initiation of the EMA’s review process. The MAA includes results from two global, Phase 3 clinical trials examining the efficacy, safety and pharmacokinetics of ALPROLIX for hemophilia B: the pivotal B-LONG study for previously treated adults and adolescents, and Kids B-LONG study for previously treated children under age 12.
June 25, 2015
12:59 EDTBIIBOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTGPSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:21 EDTFDOFamily Dollar volatility low into Q1 and outlook
Subscribe for More Information
09:03 EDTTGTTarget: Chief Merchandising and Supply Chain Officer to move to advisory role
Subscribe for More Information
08:45 EDTGPSGap initiated with a Hold at BB&T
Subscribe for More Information
08:26 EDTTGTTarget management to meet with Evercore ISI
Field trip to company headquarters to be held in Minneapolis on June 29 hosted by Evercore ISI.
June 24, 2015
11:16 EDTBIIBOptions with increasing implied volatility
Options with increasing implied volatility: WMB AMZN CMG BIIB VMW QLIK ISRG FB UA FFIV
June 23, 2015
11:00 EDTBIIBOptions with increasing implied volatility
Options with increasing implied volatility:TRIP WPZ CMG BIIB WMB AMZN ISRG VMW
07:55 EDTBIIBBiogen's Tysabri in SPMS a $1B-$2B opportunity, says Morgan Stanley
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use